Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Suspended × Alemtuzumab × Clear all

Phase

Status

Completed 78 Terminated 31 Unknown 12 Withdrawn 3 Active not recruiting 3 Suspended 1 Recruiting 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Specimen Handling 31 Magnetic Resonance Spectroscopy 21 Biopsy 16 Cyclophosphamide 14 Paclitaxel 8 Nivolumab 8 Bevacizumab 8 Gemcitabine 7 Cisplatin 7 pembrolizumab 6 Docetaxel 6 Vincristine 5 Radiotherapy 5 Radiosurgery 5 Prednisone 5 Fluorouracil 5 Doxorubicin 5 Carboplatin 5 Capecitabine 5 fludarabine 4 atezolizumab 4 Rituximab 4 Radiation 4 Oxaliplatin 4 Lenalidomide 4 Ipilimumab 4 Etoposide 4 Drug Therapy 4 Azacitidine 4 venetoclax 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01982175 2022-06-21

CLL004

Shanghai Zhangjiang Biotechnology Limited Company

Phase 2 Suspended

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡